Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessUnichem Laboratories gets USFDA nod for generic Nebivolol tablets

    Unichem Laboratories gets USFDA nod for generic Nebivolol tablets

    The approval by the US Food and Drug Administration (USFDA) for the abbreviated new drug application (ANDA) of Nebivolol tablets is for strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg, the company said in a regulatory filing.

    PTI
    March 16, 2022 / 12:45 IST
    Unichem Labs | The company has received ANDA approval for its Guanfacine tablets, USP 1 mg and 2 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of TENEX (Guanfacine) tablets 1 mg and 2 mg of Promius Pharma LLC. Guanfacine tablets are indicated in the management of hypertension. The product will be commercialized from Unichem's Ghaziabad plant.

    Unichem Laboratories on Wednesday said it has received approval from the US health regulator to market its generic version of Nebivolol tablets indicated for the treatment of hypertension.

    The approval by the US Food and Drug Administration (USFDA) for the abbreviated new drug application (ANDA) of Nebivolol tablets is for strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg, the company said in a regulatory filing.

    The product is a generic version of Bystolic of Allergan Sales, LLC, and will be commercialized from Unichem's Ghaziabad plant, it added.

    PTI
    first published: Mar 16, 2022 12:47 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347